INDV
Indivior Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$33.87
+4.38%Year over year
Reported trailing growth
- Revenue
- +13.5%
- EBITDA
- +52.8%
- EBIT
- +117.6%
- EPS
- +183.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +3.3%
- EBITDA
- +115.7%
- EPS
- +67.1%
Three-year CAGR
- Revenue
- +11.2%
- EBITDA
- +266.3%
- EBIT
- +728.1%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026